Bayer Animal Health launches Seresto™ in India
- Bayer is a world leader in parasitology and Seresto™ offers a real benefit against fleas and ticks to the pets.
- The flea and tick collar Seresto™ is one of the fastest growing brands in the Animal Health industry.
National, April 03, 2019: Bayer Animal Health in India announced the launch of Seresto™, an easy-to-use, convenient collar, which provides effective protection against fleas and ticks in dogs for up to 8 months. Since its first launch in Europe in 2011, millions of pets have been treated with Seresto™ worldwide, making it Bayer Animal Health´s biggest brand globally. Seresto™ represents a major advancement in the development of anti-parasitic prevention and treatment is registered in 79 countries around the world, including India.
Seresto™ is designed to deal with the vagaries of climate change and the resultant rise in temperatures across the globe that makes the pet community vulnerable to fleas and ticks around the year. The collar is enriched with research-based innovative polymer technology that helps in the sustained release of active ingredients in desired concentrations, for up to eight months. In order to address the concerns of potential strangulation, Seresto™ comes with two safety features; a ratchet release mechanism and predetermined breaking points (in small collar only), wherein pet’s own strength is sufficient to allow for a quick release.
Bayer Animal Health team in India introduced Seresto™ to about 500 veterinarians through a scientific session discussing the Companion Vector Borne Diseases (CVBD) landscape in India and the need for prevention. Speaking about CVBD, Dr A Sangaran, Professor, Department of Veterinary Parasitology, Madras Veterinary College, Chennai, who is also the the General Secretary of the Indian Association for the Advancement of Veterinary Parasitology (IAAVP) said, “In a tropical country like India, climatic conditions are such that the product is bound to gain popularity very quickly. With an increasing incidence of Canine Vector Borne Diseases, it is high time we control the commonly found vector ticks on dogs and take care of the pets’ surrounding environment. The protection not only concerns the well-being of the animal but also the health of families owning the pets, as the disease could be transmitted to humans if it is not addressed within time.”
Rajesh Aggarwal, Head Commercial Operations – Asia, Bayer Animal Health said, “Seresto™ is designed to free the pet owners of the monthly hassle of prevention and treatments and we are excited to launch it for the Indian market. The collar offers a real benefit to pet owners and their pets with the confidence that their dogs are well protected for a whole season against fleas and ticks wherever they go. Seresto ™ is an innovative solution in which factors for pharmaceutical quality, long-lasting efficacy, safety, and market innovation are aligned. The global success of Seresto™ confirms the belief that we offer products that really meet customers’ needs.”
Seresto™ is available as a collar in two sizes for dogs (large dog and small dog) and could be purchased in Mumbai, Chennai, Kolkata, Delhi, Pune, Hyderabad and Bangalore starting March 2019.
Seresto™ is the result of many years of multidisciplinary research utilizing Bayer´s unique experience and history in veterinary parasiticides and insecticides research and development as well as polymer chemistry and technology knowledge. Seresto™ is available as a collar in two sizes that can be worn by dogs and has been designed to stay securely in place for an up to eigh month period while ensuring safety from strangulation. Seresto™ is unique in including both one of the leading insecticides, imidacloprid and the highly effective acaricide flumethrin. These compounds are embedded in an innovative waterproof, odour-free collar made of a polymer matrix blended with a neutral oil derivative. The collar’s materials ensure that the active ingredients are consistently released over an eight-month period at an effective, low dose.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.